Company research / MED

Medifast Inc (MED)

SEC name MEDIFAST INC · CIK 0000910329 · NYSE · Miscellaneous Food Preparations & Kindred Products

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Medifast Inc reported revenue of $385.79M. Revenue fell 36.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $316.93M.

Key ratios (year ended 2025-12-31)

71.3%
Gross margin
-3.7%
Operating margin
-4.8%
Net margin
-9.4%
Return on year-end equity
-36.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-30

Headquarters locality: Baltimore · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$316.93M$385.79M$602.46M$1.07B$1.60B$1.53B$934.84M$713.67M$501.00M$301.56M$274.53M
Cost of Revenue$97.48M$110.60M$157.84M$296.20M$458.16M$398.49M$237.03M$176.81M$121.10M$73.75M$68.87M
Gross Profit$219.45M$275.19M$444.62M$775.85M$1.14B$1.13B$697.82M$536.86M$379.90M$227.81M$205.66M
R&D Expensen/a$4.30M$4.60M$4.60M$4.50M$4.40M$2.80M$2.70M$2.20M$1.50M$2.00M
Operating Income-$19.51M-$14.21M$2.88M$126.40M$184.81M$216.24M$134.16M$91.04M$69.06M$39.63M$26.86M
Depreciation & Amortization$13.85M$14.24M$12.71M$13.11M$10.98M$6.81M$4.32M$4.62M$4.43M$4.21M$5.41M
EBITDA-$5.66M$29.0K$15.59M$139.51M$195.79M$223.05M$138.47M$95.66M$73.50M$43.84M$32.26M
Net Income-$25.60M-$18.67M$2.09M$99.42M$143.57M$164.03M$102.86M$77.92M$55.79M$27.72M$17.84M
EPS (Diluted)n/a-$1.70$0.19$9.10$12.73$13.89$8.68$6.43$4.62$2.29$1.49
Total Assets$260.40M$247.97M$284.21M$309.91M$316.21M$398.33M$276.08M$194.65M$169.43M$145.93M$121.22M
Total Liabilities$64.02M$49.05M$74.10M$108.43M$161.17M$195.85M$118.84M$89.82M$60.32M$37.35M$25.20M
Shareholders' Equity$196.38M$198.92M$210.11M$201.48M$155.04M$202.47M$157.25M$104.83M$109.11M$106.56M$96.02M
Cash & Equivalents$71.91M$89.30M$90.93M$94.44M$87.69M$104.18M$163.72M$76.97M$81.36M$75.08M$52.44M
Operating Cash Flow$8.79M$6.86M$24.48M$147.66M$194.57M$94.55M$145.20M$84.26M$60.82M$43.24M$25.35M
Capital Expenditures$4.78M$5.61M$7.45M$6.48M$16.68M$34.21M$5.89M$10.06M$4.94M$3.24M$2.88M
Free Cash Flow$4.01M$1.25M$17.02M$141.17M$177.89M$60.34M$139.31M$74.20M$55.88M$39.99M$22.47M
Share Repurchasesn/a$0$0$3.60M$126.44M$56.00M$5.00M$33.11M$30.00Mn/an/a
Dividends Paid$170.0K$195.0K$715.0K$73.02M$71.62M$63.86M$53.19M$35.40M$23.16M$15.39M$11.89M
Shares Outstanding11.18M10.99M10.94M10.90M10.87M11.59M11.77M11.76M11.87M11.97M11.87M
Dividends Per Sharen/a$0.00$0.00$4.95$6.56$5.68$4.52$3.38$2.19$1.44$1.07
Weighted Average Diluted Sharesn/a10.98M10.96M10.92M11.28M11.81M11.85M12.12M12.08M12.09M11.95M
EPS (Basic)n/a-$1.70$0.19$9.13$12.82$14.01$8.74$6.62$4.67$2.32$1.51

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView